CN102836229A - Chinese medicinal composition for treating acute epidemic conjunctivitis - Google Patents

Chinese medicinal composition for treating acute epidemic conjunctivitis Download PDF

Info

Publication number
CN102836229A
CN102836229A CN2012103808124A CN201210380812A CN102836229A CN 102836229 A CN102836229 A CN 102836229A CN 2012103808124 A CN2012103808124 A CN 2012103808124A CN 201210380812 A CN201210380812 A CN 201210380812A CN 102836229 A CN102836229 A CN 102836229A
Authority
CN
China
Prior art keywords
parts
chinese medicine
medicine composition
radix
chinese medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2012103808124A
Other languages
Chinese (zh)
Other versions
CN102836229B (en
Inventor
宫月容
李卫国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nantong Hongci Pharmaceutical Co Ltd
Original Assignee
陈兴旺
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 陈兴旺 filed Critical 陈兴旺
Priority to CN 201210380812 priority Critical patent/CN102836229B/en
Publication of CN102836229A publication Critical patent/CN102836229A/en
Application granted granted Critical
Publication of CN102836229B publication Critical patent/CN102836229B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention discloses a Chinese medicinal composition for treating acute epidemic conjunctivitis, relating to the technical field of traditional Chinese medicine. The Chinese medicinal composition is prepared from Chinese medicinal materials including Chinese globeflower flower, pale butterflybush flower, medical stone, cicada shell, plantain seed, borneol, ash bark, Chinese angelica, liquoric root and mulberry root. Raw materials are plenty, simple and readily-available; and a preparation method of a preparation is simple, and is easy to operate. In the Chinese medicinal composition each medicament is matched with each other in a synergic way, so that the effects of dispelling wind, dispersing pathogenic factors, clearing away heat and toxic material and dispelling pathogenic wind for improving eyesight. The Chinese medicinal composition further has the characteristics of quick response, short treatment course and high curative rate.

Description

A kind of Chinese medicine composition of treating acute contagious conjunctivitis
Technical field
The present invention relates to the Chinese medicine technical field, be specifically related to a kind of Chinese medicine composition of treating acute contagious conjunctivitis.
Background technology
Conjunctivitis is an ophthalmology common disease, the traditional Chinese medical science be referred to as " acute and chronic conjunctivitis, common people then claim " pink eye disease ", it is by antibacterial or the caused infectiousness oculopathy of viral infection.Whenever Xia Qiu arrives, be the epidemic season of primary disease.Some coastal cities particularly are because the damp and hot bacterial reproduction much human that is beneficial to of weather can be suffered from acute conjunctivitis.Its onset is hurried, breaks with tremendous force, and no matter men and women, old and young in case infectd, just can fall ill in the several hrs.Outbreak of epidemic within the specific limits influences people's health.During this onste, photophobia arranged, shed tears, twinge and thin secretions is arranged, eyelid swelled simultaneously, the eye conjunctiva is because of the blood vessel of expansion and hemorrhagely make it to become redness.Also can change into chronic conjunctivitis like untimely treatment.
The therapeutic modality of main flow is the antimicrobial ointment or the treatment bacterial infection of putting drops in one's eyes at present, and symptom can be alleviated in 1 week after medication usually.Serious bacterial infection needs to use oral antibiotic medicament or antibiotic injection treatment, needs just can return to one's perfect health several weeks usually.
The traditional Chinese medical science claims that primary disease is acute conjunctivitis or acute and chronic conjunctivitis, is generally due to the evil poison of affection due to external wind and heat, so it is evil to loose with wind dispelling, heat-clearing and toxic substances removing is main.The medicine that uses clinically at present is few, and mostly existing medicine be decoction, has inconvenience in the use.Along with people's has produced demand widely to the recurrence of traditional traditional Chinese medical science to the Chinese medicine preparation of treating acute contagious conjunctivitis.
Summary of the invention
The Chinese medicine composition that the purpose of this invention is to provide a kind of brand-new treatment acute contagious conjunctivitis.
In order to realize the object of the invention, the technical scheme that the present invention adopts is following:
A kind of Chinese medicine composition of treating acute contagious conjunctivitis of the present invention is processed by the raw material of following weight portion: Flos Trollii 5-10 part, Flos Buddlejae 3-6 part; Maifanitum 5-10 part, Periostracum Cicadae 3-6 part, Semen Plantaginis 3-6 part; Borneolum Syntheticum 0.2-0.5 part, Cortex Fraxini 3-5 part, Radix Angelicae Sinensis 5-10 part; Radix Glycyrrhizae 2-4 part, Radix Mori 6-18 part.
The present invention treats the Chinese medicine composition of acute contagious conjunctivitis, is preferably processed by the raw material of following weight portion: 6 parts of Flos Trolliis, 4 parts of Flos Buddlejaes, 5 parts of Maifanitums; 3 parts of Periostracum Cicadaes, 3 parts of Semen Plantaginiss, 0.3 part of Borneolum Syntheticum, 3 parts of Cortex Fraxinis; 6 parts of Radix Angelicae Sinensis, 2 parts in Radix Glycyrrhizae, 10 parts of Radix Mori.
Pharmaceutical formulation of the present invention is an oral formulations, required various conventional adjuvant in the time of can adding the preparation different dosage form according to existing preparation process, and for the selection of adjuvant, the present invention does not have specific restriction.For example disintegrating agent, lubricant, adhesive etc. are prepared into any oral formulations commonly used with the method for Chinese medicinal of routine, for example can be pill, capsule, tablet, powder, granule or oral liquid etc., and are preferred but be not limited to pill.
Another object of the present invention provides a kind of method for preparing of treating the Chinese medicine composition pill of acute contagious conjunctivitis, and concrete preparation process is following:
According to the present invention's prescription, weighting raw materials material Flos Trollii, Flos Buddlejae, Maifanitum, Periostracum Cicadae, Semen Plantaginis, Borneolum Syntheticum, Cortex Fraxini, Radix Angelicae Sinensis, Radix Glycyrrhizae, Radix Mori, dry, pulverizing; Cross 200 mesh sieves, behind the abundant mix homogeneously of medicinal powder after pulverizing, the refined honey of weight such as adding; Mix homogeneously; Be divided into every part of 6g, ball is processed by group, promptly gets big honeyed pills of the present invention.
Usage and dosage: oral, the ball of being grown up twice, a time on the one.
Beneficial effect of the present invention:
1. all medicines of the present invention share, and are collaborative each other, cooperatively interact the heresy but wind dispelling looses, heat-clearing and toxic substances removing, the effect of playing dispelling pathogenic wind for improving eyesight altogether.
2. Chinese medicine composition method for preparing of the present invention is simple, is fit to produce and clinical use.
3. Chinese medicine composition raw material of the present invention is cheap and easy to get, and is no in great shortage.
4. Chinese medicine composition cure rate of the present invention is high, and the treatment short treating period does not have recurrence, and is non-stimulated, safe and reliable, has no side effect.
Below in conjunction with the clinical experiment data beneficial effect of the present invention is described
Chinese medicine composition of the present invention example surplus the diagnosis and treatment acute contagious conjunctivitis patient 200 altogether since in January, 10; Wherein 150 examples are given the big honeyed pills that makes with optimum ratio of the present invention (embodiment 1) treatment, and 50 routine giving with the sodium cromoglycate eye-drop treatment contrast as observing.
1. clinical data
Observe case totally 200 examples, be divided into two groups at random, 150 examples are organized in treatment, matched group 50 examples.2 groups of physical data statistics make it have comparability through statistical procedures, difference that promptly there are no significant (P>0.05).
2. Therapeutic Method
2.1 matched group: the external sodium cromoglycate eye-drop, every day 4 times, each 1 ~ 2, the patient with severe symptoms can increase to 6 times, 1 week of the course of treatment.
2.2 treatment group: the big honeyed pills that oral optimal drug proportioning of the present invention makes, every day 2 times, each 1 ball, 1 week of the course of treatment.
2.3 observation item: following all situation change before and after the treatment: itches, and burning sensation, photophobia is shed tears, secretions, redness, the mill sense, the upper tarsal conjunctiva cicatrix, nipple hypertrophy or folliculus, symptom has a delicate constitution.
2.4 statistical method: adopt the SPSS17.0 statistical software to analyze.
3. criterion of therapeutical effect and therapeutic outcome
3.1 criterion of therapeutical effect is with reference to relevant criterion of therapeutical effect in " disease of tcm judgement criterion of therapeutical effect ".
Recovery from illness: clinical symptoms all disappears, and the test chamber inspection is normal.Take a turn for the better: clinical symptom relief, lab testing improve or are normal.Invalid: clinical symptoms does not have being clearly better or increases the weight of.
3.2 therapeutic outcome
Two groups of clinical therapeutic efficacies are seen table 1.
Table 1 liang group clinical efficacy data
Figure 842404DEST_PATH_IMAGE002
Two groups therapeutic effect analysis: treatment group and matched group be ability efficacious therapy acute contagious conjunctivitis all; Treatment group cure rate compare with the matched group cure rate p 0.01, have utmost point significant difference.Total effective rate, treatment group be significantly higher than matched group p 0.05, have significant difference.And two groups of patients all do not find obvious adverse reaction.
According to above clinical experiment data, visible the present invention treats the Chinese medicine preparation of acute contagious conjunctivitis, and is rapid-action, short treating period, and cure rate is high, and drug safety is reliable.
Model case:
Case l: the Wang, the man, 30 years old, after going on business to the somewhere, find that two discharge of eye are purulence, eyeball congestion, photophobia, shed tears, twinge, eyelid swelled comes here to go to a doctor, and is taken big honeyed pills of the present invention with the patient, twice, one time on the one ball, recovery from illness after five days.
Case 2: together certain, man, 19 years old; Two discharge of eye increase, eyeball congestion, and photophobia, more than, the eyelid swelled of shedding tears have twinge; Once played card with the classmate who suffers from pink eye disease before patient's private prosecution is ill belongs to hour together, is diagnosed as acute contagious conjunctivitis then, is taken big honeyed pills of the present invention with the patient; Twice, one time on the one ball, recovery from illness after 6 days.
The specific embodiment
Below will further specify the present invention, but it should be appreciated by those skilled in the art that the specific embodiment of the invention and do not limit the present invention in any way through specific embodiment.Take up an official post on basis of the present invention and how all to fall within protection scope of the present invention with replacement.
EXAMPLE l: weighting raw materials material Flos Trollii 60g, Flos Buddlejae 40g, Maifanitum 50g, Periostracum Cicadae 30g, Semen Plantaginis 30g, Borneolum Syntheticum 3g, Cortex Fraxini 30g, Radix Angelicae Sinensis 60g, Radix Glycyrrhizae 20g, Radix Mori 100g, 200 mesh sieves are crossed in dry, pulverizing; Behind the abundant mix homogeneously of medicinal powder after pulverizing; Add the refined honey of 423g, mix homogeneously is divided into every part of 6g; Ball is processed by group, promptly gets.
Embodiment 2: weighting raw materials material Flos Trollii 50g, Flos Buddlejae 30g, Maifanitum 50g, Periostracum Cicadae 30g, Semen Plantaginis 30g, Borneolum Syntheticum 2g, Cortex Fraxini 30g, Radix Angelicae Sinensis 50g, Radix Glycyrrhizae 20g, Radix Mori 60g, and 200 mesh sieves are crossed in dry, pulverizing; Behind the abundant mix homogeneously of medicinal powder after pulverizing; Add the refined honey of 352g, mix homogeneously is divided into every part of 6g; Ball is processed by group, promptly gets.
Embodiment 3: weighting raw materials material Flos Trollii 100g, Flos Buddlejae 60g, Maifanitum 100g, Periostracum Cicadae 60g, Semen Plantaginis 60g, Borneolum Syntheticum 5g, Cortex Fraxini 50g, Radix Angelicae Sinensis 100g, Radix Glycyrrhizae 40g, Radix Mori 180g, and 200 mesh sieves are crossed in dry, pulverizing; Behind the abundant mix homogeneously of medicinal powder after pulverizing; Add the refined honey of 755g, mix homogeneously is divided into every part of 6g; Ball is processed by group, promptly gets.
Embodiment 4: weighting raw materials material Flos Trollii 60g, Flos Buddlejae 60g, Maifanitum 60g, Periostracum Cicadae 60g, Semen Plantaginis 60g, Borneolum Syntheticum 4g, Cortex Fraxini 50g, Radix Angelicae Sinensis 60g, Radix Glycyrrhizae 30g, Radix Mori 60g, and 200 mesh sieves are crossed in dry, pulverizing; Behind the abundant mix homogeneously of medicinal powder after pulverizing; Add the refined honey of 504g, mix homogeneously is divided into every part of 6g; Ball is processed by group, promptly gets.
Embodiment 5: weighting raw materials material Flos Trollii 80g, Flos Buddlejae 60g, Maifanitum 80g, Periostracum Cicadae 50g, Semen Plantaginis 50g, Borneolum Syntheticum 3g, Cortex Fraxini 40g, Radix Angelicae Sinensis 80g, Radix Glycyrrhizae 30g, Radix Mori 100g, and 200 mesh sieves are crossed in dry, pulverizing; Behind the abundant mix homogeneously of medicinal powder after pulverizing; Add the refined honey of 573g, mix homogeneously is divided into every part of 6g; Ball is processed by group, promptly gets.

Claims (6)

1. a Chinese medicine composition of treating acute contagious conjunctivitis is characterized in that being processed by the raw material of following weight portion: Flos Trollii 5-10 part, Flos Buddlejae 3-6 part; Maifanitum 5-10 part, Periostracum Cicadae 3-6 part, Semen Plantaginis 3-6 part; Borneolum Syntheticum 0.2-0.5 part, Cortex Fraxini 3-5 part, Radix Angelicae Sinensis 5-10 part; Radix Glycyrrhizae 2-4 part, Radix Mori 6-18 part.
2. like the Chinese medicine composition of the described treatment acute contagious conjunctivitis of claim l, it is characterized in that processing: 6 parts of Flos Trolliis, 4 parts of Flos Buddlejaes, 5 parts of Maifanitums by the raw material of following weight portion; 3 parts of Periostracum Cicadaes, 3 parts of Semen Plantaginiss, 0.3 part of Borneolum Syntheticum, 3 parts of Cortex Fraxinis; 6 parts of Radix Angelicae Sinensis, 2 parts in Radix Glycyrrhizae, 10 parts of Radix Mori.
3. according to claim 1 or claim 2 the Chinese medicine composition of treatment acute contagious conjunctivitis, it is characterized in that: said Chinese medicine composition is a peroral dosage form.
4. the Chinese medicine composition of treatment acute contagious conjunctivitis as claimed in claim 3 is characterized in that: said peroral dosage form is pill, capsule, tablet, powder, granule or oral liquid.
5. the Chinese medicine composition of treatment acute contagious conjunctivitis as claimed in claim 4 is characterized in that: said peroral dosage form is a pill.
6. the Chinese medicine composition of treatment acute contagious conjunctivitis as claimed in claim 5 is characterized in that the method for preparing of said pill is following:
Weighting raw materials material Flos Trollii, Flos Buddlejae, Maifanitum, Periostracum Cicadae, Semen Plantaginis, Borneolum Syntheticum, Cortex Fraxini, Radix Angelicae Sinensis, Radix Glycyrrhizae, Radix Mori, 200 mesh sieves are crossed in dry, pulverizing; With the abundant mix homogeneously of medicinal powder after pulverizing; The refined honey of weight such as adding, mix homogeneously is divided into every part of 6g; Ball is processed by group, promptly gets.
CN 201210380812 2012-10-10 2012-10-10 Chinese medicinal composition for treating acute epidemic conjunctivitis Active CN102836229B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201210380812 CN102836229B (en) 2012-10-10 2012-10-10 Chinese medicinal composition for treating acute epidemic conjunctivitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201210380812 CN102836229B (en) 2012-10-10 2012-10-10 Chinese medicinal composition for treating acute epidemic conjunctivitis

Publications (2)

Publication Number Publication Date
CN102836229A true CN102836229A (en) 2012-12-26
CN102836229B CN102836229B (en) 2013-10-02

Family

ID=47364132

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201210380812 Active CN102836229B (en) 2012-10-10 2012-10-10 Chinese medicinal composition for treating acute epidemic conjunctivitis

Country Status (1)

Country Link
CN (1) CN102836229B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103520552A (en) * 2013-10-25 2014-01-22 李佃场 Traditional Chinese medicine composition for treating acute conjunctivitis and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101152326A (en) * 2007-09-20 2008-04-02 吴月 Traditional Chinese medicine for treating relapse herpesvirus keratitis
CN102106977A (en) * 2009-12-24 2011-06-29 孟繁英 Externally-applied sturdy vision eyeshield liquid medicine for preventing and treating oculopathy
CN102139038A (en) * 2011-03-10 2011-08-03 赵亮 Chinese herbal preparation for treating eye diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101152326A (en) * 2007-09-20 2008-04-02 吴月 Traditional Chinese medicine for treating relapse herpesvirus keratitis
CN102106977A (en) * 2009-12-24 2011-06-29 孟繁英 Externally-applied sturdy vision eyeshield liquid medicine for preventing and treating oculopathy
CN102139038A (en) * 2011-03-10 2011-08-03 赵亮 Chinese herbal preparation for treating eye diseases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103520552A (en) * 2013-10-25 2014-01-22 李佃场 Traditional Chinese medicine composition for treating acute conjunctivitis and preparation method thereof
CN103520552B (en) * 2013-10-25 2015-04-22 青岛市中心医院 Traditional Chinese medicine composition for treating acute conjunctivitis and preparation method thereof

Also Published As

Publication number Publication date
CN102836229B (en) 2013-10-02

Similar Documents

Publication Publication Date Title
CN101843787B (en) Chinese medicament for treating benign prostatic hyperplasiabrain
CN102973770A (en) Varicella-curing Chinese medicine combination and preparing method thereof
CN101773653A (en) Chinese medicine composition for treating ablepsia and preparation method thereof
CN101703684B (en) Medicament for treating allergic purpura and preparation method thereof
CN101301414B (en) Chinese medicine for treating pelvic inflammation and preparation
CN102836229B (en) Chinese medicinal composition for treating acute epidemic conjunctivitis
CN101181285A (en) Application of astragaloside IV in the preparation of medicament for curing nervus retrogression disease
CN102579986B (en) Chinese medicinal pain-removing mixture for treating migraine
CN102988938A (en) Traditional Chinese medicine composition for treating arrhythmia or atrial fibrillation and preparation method thereof
CN103656201B (en) A kind of Chinese medicine composition of nursing for treating pink eye disease
CN102008627A (en) Traditional Chinese medicinal preparation for treating diabetic retinopathy
CN105125885A (en) Traditional Chinese medicinal composition for preventing and treating diabetes and preparation method of traditional Chinese medicinal composition
CN104324139B (en) A kind of pharmaceutical composition treating xerophthalmia
CN104306649A (en) Medicament for treating herpes zoster
CN101843786A (en) Chinese medicament for treating diabetic eyeground pathological changes
CN102716217B (en) Medicine composition for treating acne
CN101843706B (en) Chinese medicament for treating chronic kidney failure
CN102743686A (en) Pelvic inflammation-clearing capsule
CN102225154B (en) Medicament composition for treating pulmonary fibrosis
CN102670957B (en) Health-care composition and preparation method and application thereof
CN104306524A (en) Medicament for treating peripheral facial paralysis
CN101843834B (en) Chinese medicament for treating diabetic eyeground pathological changes
CN104001077A (en) Traditional Chinese medicine composition for treating urinary tract infection and application thereof
CN101843857B (en) Chinese medicament for treating diabetic eyeground pathological changes
CN115336649A (en) Tea drink composition for health food and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CUI HEFANG

Free format text: FORMER OWNER: CHEN XINGWANG

Effective date: 20130508

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 276017 LINYI, SHANDONG PROVINCE TO: 266200 QINGDAO, SHANDONG PROVINCE

TA01 Transfer of patent application right

Effective date of registration: 20130508

Address after: 266200 Jimo, Shandong, the Yellow River Road No. two, No. 182, No.

Applicant after: Cui Hefang

Address before: Three village Chu Dun Zhen 276017 Shandong province Linyi city Luozhuang District No. 89 group

Applicant before: Chen Xingwang

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: BINZHOU MEDICAL UNIVERSITY HOSPITAL

Free format text: FORMER OWNER: CUI HEFANG

Effective date: 20140716

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Gong Yuerong

Inventor after: Li Weiguo

Inventor before: Gong Yuerong

Inventor before: Li Weiguo

COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 256600 BINZHOU, SHANDONG PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20140716

Address after: 256600 No. two, No. 661, the Yellow River Road, Shandong, Binzhou

Patentee after: Binzhou Medical University Hospital

Address before: 266200 Jimo, Shandong, the Yellow River Road No. two, No. 182, No.

Patentee before: Cui Hefang

ASS Succession or assignment of patent right

Owner name: CUI HEFANG

Free format text: FORMER OWNER: BINZHOU MEDICAL UNIVERSITY HOSPITAL

Effective date: 20140805

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 256600 BINZHOU, SHANDONG PROVINCE TO: 266200 QINGDAO, SHANDONG PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20140805

Address after: 266200 Jimo, Shandong, the Yellow River Road No. two, No. 182, No.

Patentee after: Cui Hefang

Address before: 256600 No. two, No. 661, the Yellow River Road, Shandong, Binzhou

Patentee before: Binzhou Medical University Hospital

ASS Succession or assignment of patent right

Owner name: NANTONG HONGCI PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: CUI HEFANG

Effective date: 20140904

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 226200 NANTONG, JIANGSU PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20140904

Address after: 226200 Qidong chemical industry park, Jiangsu, Nantong

Patentee after: NANTONG HONGCI PHARMACEUTICAL CO., LTD.

Address before: 266200 Jimo, Shandong, the Yellow River Road No. two, No. 182, No.

Patentee before: Cui Hefang